Ningbo Houde Yimin

Ningbo Houde Yimin Pharmaceutical is a Chinese biotechnology company focused on the development of innovative small molecule therapeutics, particularly in the field of infectious diseases. The company is most notable for its co-development of deuremidevir hydrobromide (VV116), a deuterated nucleoside analog that functions as an oral antiviral against SARS-CoV-2. Developed in collaboration with the Shanghai Institute of Materia Medica and Vigonvita Life Sciences, VV116 received conditional marketing approval in China for the treatment of COVID-19. Ningbo Houde Yimin plays a critical role in the intellectual property and translational research framework for this flagship program. The company continues to collaborate with larger pharmaceutical entities like Junshi Biosciences for the global clinical advancement and commercialization of its pipeline.